戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ng thalidomide (THAL, 200 mg/d) with monthly pamidronate.
2  bisphosphonates, such as zoledronic acid or pamidronate.
3 been shown to be as effective as intravenous pamidronate.
4  renal function before the administration of pamidronate.
5 site in men treated with both leuprolide and pamidronate.
6  in cultures treated with the bisphosphonate pamidronate.
7  also increased in osteoblasts cultured with pamidronate.
8  controlled, randomized, nonblinded trial of pamidronate (30 mg intravenously every 3 mo) with vitami
9 ve either leuprolide alone or leuprolide and pamidronate (60 mg intravenously every 12 weeks).
10 ults of two randomized trials that evaluated pamidronate 90 mg administered intravenously every month
11                             Intravenous (IV) pamidronate 90 mg delivered over 1 to 2 hours every 3 to
12 ession fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zol
13 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledron
14  one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion
15 tic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion m
16 sumab, 120 mg subcutaneously, every 4 weeks; pamidronate, 90 mg intravenously, every 3 to 4 weeks; or
17 is directly, we injected postnatal rats with pamidronate, a bisphosphonate that reduces bone resorpti
18 of infected, reconstituted hu-SCID mice with pamidronate, a human V gamma 2V delta 2 T cell-specific
19 dy that treatment of murine macrophages with pamidronate, a second generation aminobisphosphonate, in
20                                              Pamidronate, a second-generation bisphosponate, has been
21 2H NMR measurements of side-chain 2H-labeled pamidronate, alendronate, zoledronate, and risedronate o
22                                              Pamidronate, an aminobisphosphonate, has been shown to l
23 icacy could be evaluated in 198 who received pamidronate and 179 who received placebo.
24 tment could be evaluated in 196 who received pamidronate and 181 who received placebo.
25 One hundred eighty-two patients who received pamidronate and 189 who received placebo were assessable
26 80 of 382 randomized patients, 185 receiving pamidronate and 195 receiving placebo.
27             Other bisphosphonates, including pamidronate and clodronate, seem to be ineffective in th
28  oxyalkyl, and sulfanylalkyl) derivatives of pamidronate and one alendronate, a molecular field analy
29                                              Pamidronate and other bisphosponates, used as supportive
30 ustained significant differences between the pamidronate and placebo groups in self-reported pain mea
31 nly used in bone resorption therapy, such as pamidronate and risedronate.
32 nitrogen-containing bisphosphonates, such as pamidronate and risedronate.
33 after lung transplant and improved with both pamidronate and time.
34 ng free divalent ion concentrations, whereas pamidronate and zoledronate appear to act on the hFOB ce
35                                              Pamidronate and zoledronate decreased hFOB cell prolifer
36                                         Both pamidronate and zoledronate increase hFOB cell bone form
37                           Intravenous use of pamidronate and zoledronic acid is associated with most
38 ed treatment with the potent bisphosphonates pamidronate and zoledronic acid seems to be well tolerat
39                           The choice between pamidronate and zoledronic acid will depend on choosing
40 t supports that oral clodronate, intravenous pamidronate, and intravenous zoledronic acid are superio
41 decreased with monthly infusions of 90 mg of pamidronate, and this effect was maintained for at least
42 t and prostate cancer patients (ibandronate, pamidronate, and zoledronic acid).
43 sphosphonates, particularly the potent agent pamidronate (Aredia), will relieve metastatic bone pain
44 t, the only agent common to all patients was pamidronate (Aredia).
45                      Treatment with 90 mg of pamidronate as a 2-hour intravenous infusion every 4 wee
46                         Monthly infusions of pamidronate as a supplement to chemotherapy can protect
47               Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior t
48                                              Pamidronate at an intraperitoneal dose of 10 mg/kg/day f
49                  Patients began therapy with pamidronate at or below the recommended dose of 90 mg, i
50                                              Pamidronate-augmented TNF-alpha production by macrophage
51 ore, pretreatment of murine macrophages with pamidronate before stimulation with IFN-gamma significan
52 all-cell lung, 183; other, 168) and 362 with pamidronate (breast, 254; myeloma, 108).
53                           The bisphosphonate pamidronate decreases skeletal complications and improve
54                                  Intravenous pamidronate disodium (90 mg) or placebo was administered
55                                              Pamidronate disodium failed to demonstrate a significant
56                      Bisphosphonates such as pamidronate disodium inhibit osteoclast-induced bone res
57 the effect of an intravenous bisphosphonate, pamidronate disodium, on pain control in metastatic pros
58 s were treated with docetaxel, docetaxel and pamidronate disodium, or docetaxel and cyclophosphamide.
59 ard dosing regimen of zoledronic acid and/or pamidronate disodium.
60                                              Pamidronate does increase the size of the osteoclasts, i
61                                     However, pamidronate does not increase survival and is associated
62                                              Pamidronate does not inhibit the gene expression of the
63 hat clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal imp
64 ed 9 or more doses of zoledronic acid and/or pamidronate during the first 10 to 15 months of therapy.
65 ned the effects of alendronate, risedronate, pamidronate, etidronate, and clodronate on apoptosis and
66 dronate (n = 34) or pamidronate (n = 17) and pamidronate followed by zoledronate (n = 33).
67                            Patients received pamidronate for 15 to 48 mo before presentation with ren
68                    The patients treated with pamidronate gained 8.8 +/- 2.5% and 8.2 +/- 3.8% in spin
69 eletal events was significantly lower in the pamidronate group (24 percent) than in the placebo group
70 had any skeletal complication was 56% in the pamidronate group and 67% in the placebo group (P = .027
71 ne resorption markers were suppressed in the pamidronate group compared with placebo.
72 rst skeletal complication was greater in the pamidronate group than in the placebo group (13.1 vs. 7.
73 ation of performance status (P=0.027) in the pamidronate group than in the placebo group.
74  of skeletal events per year was less in the pamidronate-group (1.3) than in placebo-treated patients
75 eveloped any skeletal event was lower in the pamidronate-group (P = .015).
76 nd six fractures occurred in the control and pamidronate groups, respectively (p > 0.2).
77                    The patients who received pamidronate had significant decreases in bone pain and n
78  synthase inhibitors, such as risedronate or pamidronate, had little or no activity.
79 ogen-containing bisphosphonates alendronate, pamidronate, homorisedronate, and risedronate but was le
80 nsplantation, all patients received 90 mg of pamidronate i.v. every 12 weeks, regardless of pretransp
81 fety of continued treatment with intravenous pamidronate infusions for up to 2 years.
82                      Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bon
83 trial was conducted using the bisphosphonate pamidronate intravenously in patients with new renal tra
84                                              Pamidronate is a useful adjunct to standard chemotherapy
85 riments indicate that the NH3(+)-terminus of pamidronate is close to the bone mineral surface, and a
86                                              Pamidronate is effective in reducing bony complications
87                                           IV pamidronate is recommended in women with pain caused by
88                                   Binding of pamidronate is well described by a Langmuir-like isother
89                                              Pamidronate is, therefore, a new lead compound for the s
90 nts overall, stratum 2 patients who received pamidronate lived longer than those who received placebo
91 studies suggest that bisphosphonates such as pamidronate may be efficacious.
92                                         This pamidronate-mediated augmentation of TNF-alpha productio
93 e an approximately 30-38 A2 surface area per pamidronate molecule and a deltaG = -4.3 kcal mol(-1).
94 2), clodronate (n = 1), neridronate (n = 5), pamidronate (n = 1), and zoledronate (n = 2), were inclu
95 ate therapy included zoledronate (n = 34) or pamidronate (n = 17) and pamidronate followed by zoledro
96                     Etidronate, alendronate, pamidronate, olpadronate, or amino-olpadronate (IG9402,
97                         TEDOR of [13C3, 15N] pamidronate on bone shows that the bisphosphonate binds
98 onate, were also compared with the action of pamidronate on proliferation of immortalized human fetal
99 hylamino)ethyl diphosphate, alendronate, and pamidronate on the pools of metabolites related to monot
100  therapy were randomized to receive 90 mg of pamidronate or placebo as a 2-hour intravenous infusion
101 randomly assigned to receive either 90 mg of pamidronate or placebo intravenously every 3 to 4 weeks
102 vations strongly suggest that treatment with pamidronate or zoledronate enhances the differentiation
103 reatment of PC3, DU145, and LNCaP cells with pamidronate or zoledronate significantly reduced the gro
104 studied 22 patients who received intravenous pamidronate or zoledronic acid for a duration of 3.6 yea
105 wever, the panel recommends only intravenous pamidronate or zoledronic acid in light of the use of th
106       Patients who received bisphosphonates (pamidronate or zoledronic acid) were identified.
107 no direct comparisons between clodronate and pamidronate or zoledronic acid, the superiority of one a
108  24 cycles in patients treated with 90 mg of pamidronate (P = .028, .023, and .008, respectively).
109 orubicin (Doxo) and coated with bone-seeking pamidronate (Pam) for the targeted treatment of malignan
110    Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal
111 ral mucosal tissue, we studied the effect of pamidronate (PAM), one of the BPs most commonly administ
112                                       In the pamidronate (Pam)-treated mice, but not control non-drug
113                                              Pamidronate preserved vertebral BMD during treatment and
114                                              Pamidronate prevents bone loss in the hip and lumbar spi
115                         Monthly infusions of pamidronate provide significant protection against skele
116            Treatment with the bisphosphonate pamidronate reduces skeletal complications and may also
117                                  The cost of pamidronate reflected the average wholesale price of the
118 n vivo (potency: risedronate > alendronate > pamidronate) requires expression of the Vgamma2Vdelta2 T
119                                              Pamidronate specifically binds to hydroxyapatite (HA), a
120 mplication was longer for patients receiving pamidronate than for those given placebo (P = .049).
121  complication was significantly less for the pamidronate than the placebo group at 15, 18, 21, and 24
122 alcemia were also statistically less for the pamidronate than the placebo group.
123                                           In pamidronate, the motion is well simulated by a gauche+/g
124  similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinic
125             The temporal association between pamidronate therapy and the development of renal insuffi
126                                  The cost of pamidronate therapy exceeded the cost savings from preve
127 s, and was generated by conjugating the drug pamidronate to a NIR fluorescent gold nanocluster.
128 hough survival was not different between the pamidronate-treated group and placebo patients overall,
129 skeletal complication was 13.9 months in the pamidronate-treated women and 7.0 months in the placebo
130                        Using flow cytometry, pamidronate treatment (100 microM) was shown to induce s
131                                 In addition, pamidronate treatment increased total cellular protein,
132                            We also show that pamidronate treatment increases TNF-alpha production in
133                                              Pamidronate treatment was associated with development of
134  6 to 12, the subjects were observed without pamidronate treatment.
135 e effects in vivo of the bisphosphonate drug pamidronate, used in bone resorption therapy, were inves
136 -hoc evaluation of the cost-effectiveness of pamidronate using the results of two randomized trials t
137                             We conclude that pamidronate was more effective than control in improving
138 on in mice (giving a 60% survival rate), but pamidronate was not effective.
139                                              Pamidronate was safe and well tolerated during the 21 cy
140                                              Pamidronate was tolerated well.
141                                              Pamidronate was well tolerated.
142 rseded by second-generation bisphosphonates (pamidronate), which are more potent and do not have adve
143                                              Pamidronate, which is a member of the class of bisphosph
144            Treatment subjects (PAM) received pamidronate with vitamin D and calcium at baseline and a
145 15 minutes), versus the less expensive drug, pamidronate, with its longer infusion time (2 hours).
146 dental extraction (P = .009), treatment with pamidronate/zoledronate (P = .009), longer follow-up tim

 
Page Top